Standardized assessment for panic disorder research. A conference report (Review)

Department of Psychiatry, University of Pittsburgh, Pa.
Archives of General Psychiatry (Impact Factor: 14.48). 06/1994; 51(5):346-54.
Source: PubMed


Lively controversies related to panic disorder are under active investigation by research groups around the world. However, publications from different laboratories are difficult to compare since there has been little consistency in measures or even in types of assessment used to characterize and follow up patients. Participants in the recently convened National Institutes of Health Consensus Development Conference on the Treatment of Panic Disorder noted this problem and recommended establishment of procedures to ensure comparability of studies. We organized a conference of clinical investigators whose objective was to develop a standard assessment package. Participants represented biological and psychosocial panic disorder treatment research sites in the United States and Canada. The 2-day conference resulted in agreement on a battery of assessments considered essential for panic disorder studies. The purposes of our report are to disseminate the conference conclusions and to encourage adoption of the proposed standards by clinical researchers, journal editors, Public Health Service peer review committees, and the Food and Drug Administration. We also identify some problematic issues that require further work.

1 Follower
14 Reads
  • Source
    • "To evaluate clinical severity and trait anxiety, the Panic Disorder Severity Scale (PDSS) (Lim et al., 2007b; Shear and Maser, 1994) and Anxiety Sensitivity Inventory-Revised (ASI-R) (Lim et al., 2007a; Taylor and Cox, 1998) were administered to all subjects. The PDSS was developed as a seven-item measure composed of five items including panic attacks, distress caused by panic attacks, anticipatory anxiety, agoraphobic fear/avoidance, and panic-related sensation fear/avoidance, as well as two items that rate work and social impairment (Shear et al., 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The possible involvement of microRNAs (miRNA) in psychiatric disorders has been recently recognized. Several miRNA polymorphisms have been found to be associated with panic disorder (PD) in European populations. However, the association of miRNA polymorphisms on PD has not been reported in Asian populations. We evaluated the effect of miR-22 and miR-491 polymorphisms on susceptibility to PD in a Korean population. Methods: Genotyping for four polymorphic variants of the primary miRNA (pri-miRNA) regions of miR-22 (rs8076112 and rs6502892) and miR-491 (rs4977831 and rs2039391) was performed using blood samples of 341 Korean patients with PD and 229 healthy control subjects. To evaluate PD phenotypes, the Panic Disorder Severity Scale (PDSS) and Anxiety Sensitivity Inventory-Revised (ASI-R) were administered. Results: Three single-nucleotide polymorphisms (SNPs) were found to be associated with PD: rs8076112 miR-22 and rs4977831 and miR-491 rs2039391. The rs8076112C/rs6502892C haplotypes of miR-22 and rs4977831G/rs2039391G and rs4977831A/rs2039391A haplotypes of miR-491 were significantly overrepresented in patients with PD than in healthy control subjects. In combination analysis, miR-22 rs8076112AC/rs6502892CC and rs8076112CC/rs6502892CC and miR-491 rs4977831AG/rs2039391AA were more frequent in patients with PD. Among the phenotype assessments, ASI-R scores were significantly associated with miR-22 rs6502892 in the subgroup with the agoraphobic phenotype. Limitations: The results should be considered preliminary due to the relatively small sample size and the selection of only four SNPs. Conclusions: This is the first report to show possible associations of miR-22 and miR-491 with genetic susceptibility to PD in a Korean population.
    Journal of Affective Disorders 09/2015; 188:118-126. DOI:10.1016/j.jad.2015.08.064 · 3.38 Impact Factor
  • Source
    • "The BAI has demonstrated good psychometric qualities (Beck & Steer, 1984; Steer, Ranieri, Beck, & Clark, 1993). Furthermore, it has been recommended as a measure of anxiety in psychotherapy research (Crits-Cristoph & Conelly, 1997) and as a measure of anxiety in panic disorder (Shear & Maser, 1994). Cronbach's a for the BAI in the study was .91. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of cognitive behavioural therapy (CBT) for panic disorder with or without agoraphobia (PD) is well-established; however, little is known about the underlying change processes of clinical improvement during therapy. According to cognitive theories, CBT for PD primarily works by changing catastrophic misinterpretations of bodily symptoms and panic attacks. However, panic self-efficacy, i.e. the perceived ability to cope with panic attacks, has also been suggested as an important change mechanism in CBT for PD. The aim of the study was to investigate if change in catastrophic misinterpretations and panic self-efficacy mediated change in the level of anxiety during the course of thirteen sessions of group CBT for PD. Forty-five participants completed weekly self-report measures of the possible cognitive mediators and the level of anxiety throughout therapy. The results indicated that within-person change in panic self-efficacy in one session, but not in catastrophic misinterpretations, predicted within-person level of anxiety symptoms the following week. However, in a reversed analysis, prior change in level of anxiety symptoms also predicted change in panic self-efficacy the following session. These results support panic self-efficacy as a mediator of change in CBT for PD, although a reciprocal causal relationship between panic self-efficacy and level of anxiety seems to be implied.
    Behaviour Research and Therapy 06/2013; 51(9):579-587. DOI:10.1016/j.brat.2013.06.002 · 3.85 Impact Factor
  • Source
    • "Currently, selective serotonin-reuptake inhibitors (SSRIs) are indicated as the first-line treatment for PD. SSRIs are relatively safe and have few side effects.10) Escitalopram is the most recently developed SSRI and is used widely for the treatment of patients with PD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Panic disorder is characterized by recurrent panic attacks, persistent concerns about additional attacks, and worry about the implications of the attack or significant changes in behavior related to the attacks. We examined the efficacy of 24-week naturalistic, open-label escitalopram treatment in terms of the response and remission rates and functional disability in 119 adult Korean patients with panic disorder from 6 clinical centers in South Korea. Clinical severity and functional impairment were assessed at baseline and at 4, 12, and 24 weeks after the treatment using the Panic Disorder Severity Scale and Sheehan Disability Scale. Ninety-six patients (80.7%) showed a treatment response, and 87 patients (73.1%) had attained remission after 24 weeks of escitalopram treatment. Continuous improvement in the Panic Disorder Severity Scale and Sheehan Disability Scale scores was found over the 24 weeks of treatment. These findings suggest that escitalopram treatment is very effective for panic disorder in terms of both response and remission rates and that long-term pharmacotherapy with escitalopram continuously improved panic symptoms and functional disability in Korean patients with panic disorder.
    Clinical Psychopharmacology and Neuroscience 04/2012; 10(1):44-8. DOI:10.9758/cpn.2012.10.1.44
Show more